RxDoctor Payments DataLook up a doctor →

Brian Persing, MD

Medical Oncology · Pascagoula, MSNPI 1538189543

Payments from drug & device makers

$510,312in general payments, 2019–2025

Across 988 payments — averaging $516.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$221K
  • AstraZeneca$116K
  • Regeneron Healthcare Solutions, Inc.$59K
  • Jazz Pharmaceuticals Inc.$23K
  • E.r. Squibb & Sons, L.L.C.$17K
  • Ipsen Bioscience Inc.$15K
  • plus $59K from 54 others

What the payments were for

  • Consulting fees$85,51733%
  • Speaking & faculty fees$148,18256%
  • Travel & lodging$11,4824%
  • Food & beverage$16,9246%
  • Education$5270%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck63$220,970
AstraZeneca(2 entities)128$115,902
Regeneron Healthcare Solutions, Inc.73$58,888
Jazz Pharmaceuticals Inc.19$23,389
E.r. Squibb & Sons, L.L.C.54$17,047
Ipsen Bioscience Inc.2$14,600
AbbVie14$13,170
Genentech USA, Inc.41$11,966
Johnson & Johnson(2 entities)67$10,972
Regeneron5$4,539
Mirati Therapeutics, Inc.5$3,676
Incyte Corporation33$2,519
Bristol Myers Squibb51$2,036
Daiichi Sankyo Inc.20$2,031
Novartis79$1,458
Lilly USA, LLC18$1,366
Eisai Inc.39$704
Pfizer46$676
Sanofi23$398
Amgen21$334
Astellas Pharma US Inc13$271
Takeda Pharmaceuticals U.S.A., Inc.10$254
Exelixis Inc.8$160
Gilead10$136
Stemline Therapeutics Inc.7$128
Blueprint Medicines Corporation6$125
Geron Corporation1$123
Acceleron Pharma, Inc.2$111
Rigel Pharmaceuticals, Inc.6$101
GSK6$99
Bayer6$99
AVEO Pharmaceuticals, Inc.2$94
Sobi, Inc5$93
Boehringer Ingelheim5$90
Pharmacyclics LLC, An Abbvie Company2$89
Tersera Therapeutics LLC4$88
Beigene USA, Inc.5$85
Pharmaessentia USA Corporation4$83
Beone Medicines USA, Inc.4$81
EMD Serono, Inc.5$78
Taiho Oncology, Inc.5$78
Array Biopharma Inc5$75
Ipsen Biopharmaceuticals, Inc4$69
Deciphera Pharmaceuticals Inc.4$62
Sumitomo Pharma America, Inc.1$61
Octapharma USA, Inc.3$60
Genmab U.S., Inc.4$59
Teva Pharmaceuticals USA, Inc.4$57
Karyopharm Therapeutics Inc.4$57
Adaptive Biotechnologies Corporation2$55
Pharmacosmos Therapeutics Inc.3$52
Seagen Inc.3$52
ADC Therapeutics America, Inc.3$50
Sanofi-aventis U.S. LLC2$47
Springworks Therapeutics, Inc.3$46
Sanofi US Services Inc.2$40
Myovant Sciences Inc.3$37
Lexicon Pharmaceuticals, Inc.2$34
Dendreon Pharmaceuticals LLC2$34
Immunogen, Inc.2$32

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$510,312 in reported general payments places this provider in the 95th percentile of 20 medical oncology providers in Mississippi.

See all medical oncology providers in Mississippi

Medicare billing

Part B allowed, 2024
$59,767
Medicare patients
144
Services billed
561

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PomalystPomalidomide12$282,147
JakafiRuxolitinib Phosphate13$179,466
NubeqaDarolutamide12$165,425
LonsurfTrifluridine/Tipiracil Hcl11$107,343
Fentanyl60$7,182
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen91$3,295
Morphine Sulfate ErMorphine Sulfate37$1,359
Morphine Sulfate29$1,318
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen27$639
Dexamethasone15$464
Gabapentin33$460
Oxycodone Hcl21$427
Letrozole26$304
Ondansetron OdtOndansetron20$299
Hydromorphone Hcl14$228

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Pomalyst$17,047$282,14712 claims
Incyte CorporationJakafi$2,519$179,46613 claims
BayerNubeqa$99$165,42512 claims
Taiho Oncology, Inc.Lonsurf$78$107,34311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 20 medical oncology providers in Mississippi.

Other medical oncology in Pascagoula

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →